GSK's Bepirovirsen Enters EMA Review As Potential First-In-Class Functional Cure For Chronic Hepatitis B With Statistically Significant Phase III Results

GSK has submitted Bepirovirsen for review by the European Medicines Agency (EMA) as a potential first-in-class functional cure for chronic hepatitis B (CHB), supported by statistically significant results from its Phase III B-Well trials. Chronic hepatitis B affects nearly 3.2 million people in Europe and is a leading cause of liver cancer.